A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs CV 301 (Primary) ; Durvalumab (Primary) ; Bevacizumab; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Nov 2018 According to a Bavarian Nordic media release, the first patient has been dosed in this study.
- 25 Sep 2018 Status changed from not yet recruiting to recruiting.
- 10 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.